New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT --

DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three sub-analyses from the REDUCE-IT^® trial describing the impact of VASCEPA^®/VAZKEPA^® (icosapent ethyl - IPE) administration on cardiovascular disease (CVD) risk associated with Cardiovascular-Kidney-Metabolic (CKM) syndrome, major adverse cardiovascular events (MACE) stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride rich lipoprotein cholesterol (TRL-C) levels, and on hospitalizations. All three post hoc analyses showed significant reductions in cardiovascular risk and outcomes in the populations studied. The data was presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain.